别名 Decaprenylphospho-beta-D-ribofuranose 2-dehydrogenase、Decaprenylphosphoryl-beta-D-ribofuranose 2'-epimerase subunit DprE1、Decaprenylphosphoryl-beta-D-ribofuranose 2'-oxidase + [3] |
简介 Component of the DprE1-DprE2 complex that catalyzes the 2-step epimerization of decaprenyl-phospho-ribose (DPR) to decaprenyl-phospho-arabinose (DPA), a key precursor that serves as the arabinose donor required for the synthesis of cell-wall arabinans (PubMed:16291675, PubMed:19299584). DprE1 catalyzes the first step of epimerization, namely FAD-dependent oxidation of the C2' hydroxyl of DPR to yield the keto intermediate decaprenyl-phospho-2'-keto-D-arabinose (DPX) (PubMed:22733761). The intermediate DPX is then transferred to DprE2 subunit of the epimerase complex, most probably through a 'substrate channel' at the interface of DprE1-DprE2 complex (PubMed:25789990). Can also use farnesyl-phosphoryl-beta-D-ribofuranose (FPR) as substrate in vitro (PubMed:25427196). Appears to be essential for the growth and survival of M.tuberculosis (PubMed:12657046, PubMed:24517327).
DprE1 is a highly vulnerable and fully validated tuberculosis drug target. |
靶点 |
作用机制 DprE1抑制剂 |
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 DprE1抑制剂 |
原研机构 |
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 DprE1抑制剂 |
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2025-04-13 |
申办/合作机构 ![]() [+1] |
开始日期2024-01-09 |
申办/合作机构 |
开始日期2023-09-21 |
申办/合作机构 |